Last reviewed · How we verify

Jadran Galenski laboratorij d.d. — Portfolio Competitive Intelligence Brief

Jadran Galenski laboratorij d.d. pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vizol S DIGI EYE eye drops Vizol S DIGI EYE eye drops phase 3 prostaglandin analog PGF2α receptor Ophthalmology
Vizol S LIPID BALANCE eye drops Vizol S LIPID BALANCE eye drops phase 3 eye lubricant Ophthalmology
ophthalmic saline eye drops ophthalmic saline eye drops phase 3 Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jadran Galenski laboratorij d.d.:

Cite this brief

Drug Landscape (2026). Jadran Galenski laboratorij d.d. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jadran-galenski-laboratorij-d-d. Accessed 2026-05-16.

Related